In Singapore for #SWITCH2026? XtalPi is on the main stages and hosting an #AIforScience partner event on Oct 28. • Dr. Lipeng Lai on how AI and TechBio are reshaping drug discovery. • Dr. Peiyu Zhang on what could drive the next inflection point in materials AI. We’ll also cover how AI, agents, and robotic labs are advancing drug discovery at our partner event. Registration👇

Our first siRNA PCC is here, developed internally in just 9 months with Kodexia™. The IgAN candidate’s IC50 was tens of times lower than clinical-stage references in vitro. In nonhuman primates, one dose suppressed the target protein for months, longer than either reference.🧵

Automated labs can run thousands of reactions. But every new product poses the same question: how much did we actually make? XtalPi is open-sourcing lcms2yield, an AI model integrated into our robotic labs that estimates yields without product-specific calibration curves. 🧵

Ailux, XtalPi’s AI-native biotech subsidiary, welcomes Lloyd S Miller, MD, PhD as Chief Medical Officer. With 25 years of experience in drug R&D, including leadership at Johnson & Johnson Innovative Medicine, Dr. Miller will lead clinical development of Ailux’s biologics pipeline toward first-in-human studies targeted for 2027.

1/100th the concentration. Comparable hair-growth scores to 5% minoxidil in a DHT-induced androgenetic alopecia mouse model. XtalPi’s hair-loss candidate has entered IND-enabling studies, targeting dormant follicle stem cells through a different biological pathway. 🧵1/6